Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368690 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL3367512 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL3367506 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL830372 | 0.86 | HDAC1 (0.80) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL830373 | 0.86 | HDAC1 (0.80) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL833123 | 0.84 | HDAC1 (0.80) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL833122 | 0.84 | HDAC1 (0.80) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL3367353 | 0.84 | HDAC1 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL13118142 | 0.84 | HDAC1 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC11 | |
| SCHEMBL833750 | 0.84 | HDAC1 (0.78) | HDAC1HDAC8HDAC6HDAC2HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673349-B1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2010-06-30 | — | — | EP | claimed |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2019-09-19 | — | — | US | disclosed |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2019-09-19 | — | — | US | disclosed |
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2017-12-21 | — | — | US | disclosed |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2017-12-21 | — | — | US | disclosed |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2017-12-21 | — | — | US | disclosed |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-10-07 | — | — | US | disclosed |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-10-07 | — | — | US | disclosed |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-10-07 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| EP-1673349-B1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2010-06-30 | — | — | EP | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC6 10/4885 |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC6 10/4885 |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC8 4/4885HDAC6 10/4885 |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC6 10/4885 |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC6 10/4885 |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.